References
- Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377–380
- Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002a; 99: 1527–1531
- Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002b; 8: 121–127
- Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin–VEGF fusion proteins. Bioconj Chem 2001; 12: 1066–1073
- Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G, Mazie JC. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19: 1525–1533
- Bockmann M, Drosten M, Putzer BM. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 2005; 7: 179–188
- Coll JL, Wagner E, Combaret V, Metchler K, Amstutz H, Iacono-Di-Cacito I, Simon N, Favrot MC. In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer. Gene Ther 1997; 4: 156–161
- Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8: 341–348
- Ho IA, Lam PY, Hui KM. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum Gene Ther 2004; 15: 719–732
- Kashentseva EA, Seki T, Curiel DT, Dmitriev IP. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 2002; 62: 609–616
- Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001; 5: 308–313
- Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 2003; 90: 509–517
- Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815–14820
- Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, Chandler LA, Kerr DJ, Seymour LW. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther 2002; 9: 543–552
- Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364–366
- Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999; 274: 11593–11598
- Shukla GS, Krag DN. Phage display selection for cell-specific ligands: Development of a screening procedure suitable for small tumor specimens. J Drug Target 2005a; 13: 7–18
- Shukla GS, Krag DN. Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library. Oncol Rep 2005b; 13: 757–764
- Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Kramer S, Altmann A, Eisenhut M, Haberkorn U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005; 11: 139–146